Ernexa Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.95 USD (Nov 2, 2026, 4:00 PM EST) · Market cap 3.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Details
| Name | Ernexa Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7 |
| Founded | 2018 |
| Ceo | Sanjeev Luther |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1140824079 |
| Cusip | 114082407 |
| Cik | 748592 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Sanjeev Luther | Chief Executive Officer, President and Director |
| Mark J. Keeley CPA, CITP, M.B.A. | Chief Financial Officer |
| Deborah Vee Wild | Head of CMC and Operations |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Dorothy J. Clarke | General Counsel |
Contact
| Address | 1035 Cambridge Street, Suite 18A, Cambridge, Massachusetts 02141, United States |
| Phone | 617 798 6700 |
| Website | https://www.ernexatx.com |